Antimalarial drug resistance and combination chemotherapy

Antimalarial drug resistance

Antimalarial drug resistance is of great concern in the WHO South-East Asia (SEA) Region. A high degree of resistance of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine is prevalent in this Region. Multidrug resistance is prevalent in some parts of the Greater Mekong Sub-region. Artemisinin and its derivatives in combination with other effective partner drugs, which showed fa...

Antimalarial drug resistance.

Malaria, the most prevalent and most pernicious parasitic disease of humans, is estimated to kill between one and two million people, mainly children, each year. Resistance has emerged to all classes of antimalarial drugs except the artemisinins and is responsible for a recent increase in malaria-related mortality, particularly in Africa. The de novo emergence of resistance can be prevented by ...

Antimalarial Drug Resistance

Malaria is a hematoprotozoan parasitic infection transmitted by certain species of anopheline mosquitoes. Four species of Plasmodium commonly infect humans, but Plasmodium falciparum, accounts for the majority of instances of morbidity and mortality. There has been a resurgence of interest in malaria in recent years because the efforts at control have foundered after the failure of the global e...

History and importance of antimalarial drug resistance.

The emergence of Plasmodium falciparum resistance to widely used antimalarial drugs such as chloroquine (CQ) has made malaria control and treatment much more difficult. This is particularly dramatic for Africa, as few affordable alternatives are available. Drug pressure has been identified as one of the key factors for the emergence and spread of resistance. The contribution of the extensive us...

Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery.